Advertisement
DIA
Drug Information Association Logo

Regulatory Affairs

Comprehensive training on current regulations and their practical application

This certificate program will provide the fundamental skills you need to do your job. Topics include but are not limited to:

  • US regulatory affairs: the IND and NDA and postmarketing
  • European regulatory requirements
  • Preparing for FDA meetings
  • Post-approval regulatory requirements
  • Regulatory requirements for product labeling & advertising
  • Electronic submissions
  • Quality assurance
  • Biosimilars
  • Biologic products
  • Drug development
Certificate Program Requirements
To successfully complete the certificate program, learners must complete 28 Core units and 16 Elective units; courses included in this program are noted below:

Course Title
Format
PM Certificate Program Units

Adverse Event Reporting Requirements: IND and Post-marketing

Online
3 Elective Units
Art of Writing a Clinical Overview
Online and Face-to-face
4 Elective Units
Basics of the IND

Online
6 Core Units

Basics of the NDA

Online
6 Core Units
Development of a Clinical Study Report
Online and Face-to-face
4 Elective Units

Electronic Submissions: The Next Era of Electronic Submissions

Face-to-face
4 Elective Units
European Regulatory Affairs: Keeping your Finger on the Pulse of Marketing Authorizations
Face-to-face
6 Core Units

Global Considerations for Regulatory Strategy Development

Face-to-face
8 Elective Units

How to Prepare for a Safety Inspection

Online
3 Elective Units

Interactions with the FDA during the IND/NDA Phases

Online
2 Core Units

Key Considerations for the Development and Marketing of Biosimilar Products

Face-to-face
8 Elective Units
Navigating Chemistry, Manufacturing and Controls Through the Drug Development Process
Face-to-face
8 Elective Units

Overview of Drug Development

Face-to-face
4 Elective Units

Overview of Drug Development in Japan

Online
6 Elective Units

Preparing for a US FDA Advisory Committee Meeting

Face-to-face
4 Core Units

Regulatory Affairs for Biologics

Face-to-face
8 Core Units

Regulatory Affairs: The IND, NDA and Postmarketing

Face-to-face
16 Core Units
Regulatory Aspects of Prescription Drug/Biologics Advertising and Promotional Labeling
Online
2 Core Units

Strategies for Good Clinical Practice Audits

Online
4 Elective Units

Supplements and Other Changes to an Approved Application

Online
1 Elective Unit
* additional meetings and webinars are available to meet the elective unit requirements and will be noted in the upcoming schedule list below

Downloads

Certificate Program Requirements

Electives (Must successfully complete 16 Regulatory Affairs Certificate Program (RCP) Elective Units)
Course NameCE HoursProgram Units
Product Labeling
11/27/2002- 09/25/2016
Location: Online
ACPE 2.00, IACET 2.001.00
Regulatory Issues
11/19/2002- 09/25/2016
Location: Online
ACPE 4.00, IACET 4.001.00
Crisis Management
10/16/2002- 09/25/2016
Location: Online
ACPE 1.50, IACET 1.501.00
Complimentary Patient-Centeredness and Engagement in Clinical Research: Opportunities for Industry
02/06/2014- 01/31/2015
Location: Online
None Available1.00
The Use of Mobile Medical Applications as Companions
02/12/2014- 01/31/2015
Location: Online
None Available1.00
Emerging Technologies to Rare Disorder Drug Development: Promises and Pitfalls
02/25/2014- 02/28/2015
Location: Online
None Available1.00
Emerging Technologies to Rare Disorder Drug Development: Promises and Pitfalls
02/25/2014- 02/28/2015
Location: Online
None Available1.00
Implementation of the FDASIA Patient Provisions
03/05/2014- 02/28/2015
Location: Online
None Available1.00
Development of a Clinical Study Report
03/13/2014- 03/12/2015
Location: Online
None Available4.00
The Future of Personalized Medicine and Companion Diagnostics
03/20/2014- 03/31/2015
Location: Online
None Available1.00
Seven-Part Series on Pediatric Drug Development - Part 1: Overall Challenge: The Vision of Better Medicines for Children
04/16/2014- 10/13/2015
Location: Online
None Available1.00
Strategies for Successfully Introducing REMS to Your Organization: From Development and Implementation and Internal and External Evaluation
04/25/2014- 10/31/2014
Location: Online
None Available1.00
Good Pharmacovigilance Practice: How Good has it Proven to be for Industry?
04/29/2014- 11/01/2014
Location: Online
None Available1.00
Designed for Success: Utilizing Protocol Quality by Design (QbD) to Plan Clinical Studies
05/01/2014- 04/30/2015
Location: Online
None Available1.00
How to Prepare for a Safety Inspection
05/08/2014- 05/07/2015
Location: Online
None Available3.00
Generic Drug Labeling Proposed Rule and Safety Updates
05/16/2014- 06/01/2015
Location: Online
None Available1.00
Big Data: Impact of Health Care Reform on Collaborations and Strategies
05/19/2014- 11/18/2014
Location: Online
None Available1.00
Pharmacovigilance and Risk Management: Patient Perspective
05/22/2014- 05/21/2015
Location: Online
None Available1.00
China Update: Regulatory Changes and Implications
05/28/2014- 11/27/2014
Location: Online
None Available1.00
Supplements and Other Changes to an Approved Application
06/10/2014- 06/09/2015
Location: Online
None Available1.00
Seven-Part Series on Pediatric Drug Development - Part 3: Regulatory Framework EU
06/18/2014- 10/13/2015
Location: Online
None Available1.00
Variations in the European Union: CMC/Quality Changes
06/26/2014- 06/25/2015
Location: Online
None Available1.00
Five-Part Series on Fundamentals of Clinical Pharmacology for Drug Development - Part 1: Fundamentals of Clinical Pharmacology: Pharmacokinetics
07/10/2014- 11/05/2015
Location: Online
None Available1.00
Seven-Part Pediatric Drug Development Webinar Series - Part 4: Dosing in Children
07/15/2014- 10/13/2015
Location: Online
None Available1.00
Seven-Part Series on Pediatric Drug Development - Part 2: Regulatory Framework US Overview
07/15/2014- 10/13/2015
Location: Online
None Available1.00
Pharmacovigilance and Global Harmonization Updates
07/24/2014- 07/23/2015
Location: Online
None Available1.00
Adverse Event Reporting Requirements: IND and Postmarketing
07/24/2014- 07/23/2015
Location: Online
None Available3.00
Five-Part Series on Fundamentals of Clinical Pharmacology for Drug Development - Part 2: Fundamentals of Clinical Pharmacology: Pharmacodynamics
08/07/2014- 11/05/2015
Location: Online
None Available1.00
Seven-Part Series on Pediatric Drug Development - Part 5: Technical Development: Pediatric Formulations
08/13/2014- 10/13/2015
Location: Online
None Available1.00
Five-Part Series on Fundamentals of Clinical Pharmacology For Drug Development - Part 3: Principles of Modeling and Simulation
09/05/2014- 11/05/2015
Location: Online
None Available1.00
Art of Writing a Clinical Overview
09/11/2014- 09/10/2015
Location: Online
None Available4.00
Seven-Part Series on Pediatric Drug Development - Part 6: Preclinical Toxicology & Safety
09/09/2014- 10/13/2015
Location: Online
None Available1.00
Clinical Trials Transparency 3-Part Series: Moving the Debate Forward - Realizing the Benefits of Providing Greater Access to Clinical Trial Data: Part 1 - Paving the Way for Greater Access To Data
09/09/2014- 11/11/2015
Location: Online
None Available1.00
The Role of the Clinical Data Manager
10/08/2014- 10/07/2015
Location: Online
None Available1.00
Five-Part Series on Fundamentals of Clinical Pharmacology for Drug Development - Part 4: Determining the Safe First Human Dose
10/09/2014- 11/05/2015
Location: Online
None Available1.00
DIA’s Annual Canadian Meeting: Thinking Globally, Acting Locally for The Well-Being of the Patient
10/28/2014- 10/29/2014
Location: Ottawa, Canada
ACPE 9.00, IACET 10.757.00
Patient Engagement throughout the Full Spectrum of Drug Development: An Interactive Workshop for Life Science Companies and Patient Groups
10/29/2014- 10/30/2014
Location: Washington, DC, United States
IACET 12.758.00
DIA Meeting on Combination Products
10/29/2014- 10/29/2014
Location: Washington, DC, United States
IACET 7.004.00
DIA Meeting on Companion Diagnostics
10/30/2014- 10/30/2014
Location: Washington, DC, United States
IACET 7.004.00
Advanced Signal Detection - Tools, Triage, Evaluation, and Escalation
11/03/2014- 11/04/2014
Location: Washington, DC, United States
IACET 14.008.00
Navigating Chemistry, Manufacturing & Controls Through the Drug Development Process
11/03/2014- 11/04/2014
Location: Horsham, PA, United States
IACET 12.758.00
Five-Part Series on Fundamentals of Clinical Pharmacology for Drug Development - Part 5: Assessment of QT Prolongation
11/06/2014- 11/06/2014
Location: Online
ACPE 1.50, IACET 1.501.00
Five-Part Series on Fundamentals of Clinical Pharmacology for Drug Development - Part 5: Assessment of QT Prolongation
11/06/2014- 11/05/2015
Location: Online
None Available1.00
Pediatric Research Conference 2014: Transforming the Pediatric Research Landscape through Innovation and Forward Thinking
11/06/2014- 11/07/2014
Location: North Bethesda, MD, United States
IACET 10.506.00
Clinical Trials Transparency 3-Part Series: Moving the Debate Forward - Realizing the Benefits of Providing Greater Access to Clinical Trial Data: Part 3 - Understanding the Legislation Landscape: Regulatory Updates from the FDA and EMA
11/12/2014- 11/12/2014
Location: Online
IACET 1.501.00
Proarrhythmia
11/19/2014- 11/19/2014
Location: Online
ACPE 2.00, IACET 2.001.00
Impact on Drug Development of Novel Translational Safety Biomarkers for Improved Detection of Drug-Induced Acute Kidney Injury
11/20/2014- 11/20/2014
Location: Online
ACPE 1.50, IACET 1.501.00
Facets of Drug-Induced Kidney Injury and Regulatory Perspective
12/03/2014- 12/03/2014
Location: Online
ACPE 1.50, IACET 1.501.00
The Basics of Clinical Data Management From Start to End
12/03/2014- 12/03/2014
Location: Washington, DC, United States
IACET 7.004.00